The biological role of the Fas/FasL system during tumor formation and progression

Seminars in Cancer Biology

Volumn 12, Issue 4, 2002, Pages 309-315

  Reichmann, Ernst ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Anti cancer therapy; Apoptosis; Fas Fas ligand; Tissue homeostasis; Tumor development

Indexed keywords

CASPASE 8; FAS ANTIGEN; FAS LIGAND; MESSENGER RNA; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; RAS PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; AUTOIMMUNITY; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL DEATH; CELL SURVIVAL; IMMUNE RESPONSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; TUMOR GROWTH;

EID: 0036377840     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(02)00017-2     Document Type: Article

References (60)

1. Social controls on cell survival and cell death
2. Programmed cell death and the control of cell survival: Lessons from the nervous system
3. A cell-killing mono-clonal antibody (anti-Fas) to a cell surface antigen co-down-regulated with the receptor of tumor necrosis factor
4. Monoclonal antibody-mediated tumor regression by induction of apoptosis
5. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
6. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
7. Modularity in the TNF-receptor family
8. A novel domain within the 55 kD TNF receptor signals cell death
9. Activation interferes with the APO-1 pathway in mature human T cells
10. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells
11. Metalloproteinase-mediated release of human Fas ligand
12. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases
13. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles
14. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
15. Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover
16. Expression of the Fas ligand in cells of T cell lineage
17. Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells
18. Identification of two NF-kappa B sites in mouse CD95 ligand (Fas ligand) promoter: Functional analysis in T cell hybridoma
19. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1
20. NF-kappa B-dependent Fas ligand expression
21. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor
22. Caspases: Killer proteases
23. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia
24. Autoproteolytic activation of pro-caspases by oligomerization
25. Two CD95 (APO-1/Fas) signaling pathways
26. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations
27. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling
28. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells
29. Bcl-xL functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells
30. FAP-1: A protein tyrosine phosphatase that associates with Fas
31. Inhibition of death receptor signals by cellular FLIP
32. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation
33. Anti-Fas on nonhematopoietic tumors: Levels of Fas/ APO-1 and bcl-2 are not predictive of biological responsiveness
34. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas in human esophageal cancer
35. Fas expression and function in normal and malignant breast cell lines
36. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?
37. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas
38. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
39. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
40. Human lung carcinomas express Fas ligand
41. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes
42. Fas ligand-induced apoptosis as a mechanism of immune privilege
43. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance
44. A role for CD95 ligand in preventing graft rejection
45. Lung lymphocyte elimination by apoptosis in the murine response to intratracheal particulate antigen
46. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by down regulating the expression of Fas
47. Fas-dependent tissue turnover is implicated in tumor cell clearance
48. Death receptors: Signaling and modulation
49. Apoptosis induced by death receptors
50. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
51. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
52. Safety and antitumor activity of recombinant soluble Apo2 ligand
53. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
54. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site
55. Steering anti-cancer drugs away from the TRAIL
56. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
57. Cholangiocarcinomas express Fas ligand and disable the Fas receptor
58. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function
59. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy
60. A genetic model for colorectal tumorigenesis